The BALB/c-derived 4T1.2 tumor is an aggressive mammary carcinoma that spontaneously metastasizes to multiple organs within days of main growth. with the mouse DR5-specific monoclonal antibody MD5-1 to induce quick and strong tumor cell apoptosisin vitroandin vivo. Importantly, using a preclinical mouse breast cancer model, we show CGS 21680 HCl that this combination of vorinostat and MD5-1 is usually safe and induces regression of established tumors, whereas single agent treatment experienced little or no effect. Functional analyses revealed that rather than mediating enhanced tumor cell apoptosis via the CGS 21680 HCl simultaneous activation of the intrinsic and extrinsic apoptotic pathways, vorinostat augmented MD5-1-induced apoptosis concomitant with down-regulation of the intracellular apoptosis inhibitor cellular-FLIP (c-FLIP). These data demonstrate that combination therapies including HDACi and activators of the TRAIL pathway can be efficacious for the treatment of malignancy in experimental mouse models. Histone deacetylase inhibitors (HDACi) are an exciting class of anticancer drugs currently in early phase clinical trials for the treatment of hematological malignancies and solid tumors (1,2). These brokers can elicit a range of biological responses that affect tumor growth and survival, including inhibition of tumor cell cycle progression, induction of tumor cell-selective apoptosis, suppression CGS 21680 HCl of angiogenesis, and modulation of immune responses. Although HDACi show promise as single agents, given their pleiotropic anticancer activities and the apparent lack of toxicity to normal cells, their use in combination with other brokers may improve their breadth of application. Already, HDACi have been shown to function synergisticallyin vitrowith a host of structurally and functionally diverse chemical compounds and biologically active polypeptides (1,3). With a more complete understanding of the molecular mechanisms of action of HDACi, combination studies based on a strong mechanistic rationale are now possible. Induction of apoptosis plays a key role in mediating the antitumor effects of HDACi in preclinical models (46), and the molecular events underpinning this process are now being elucidated. HDACi can induce tumor cell apoptosis through activation of either the extrinsic (death receptor) or intrinsic (mitochondrial) pathway depending on the cell type and/or the HDACi under investigation (1). Activation of the extrinsic pathway by HDACi occurs through transcriptional up-regulation of various TNF receptor super-family users and/or their cognate ligands. Indeed, studies by different groups using various genetic or biological means to inhibit death receptor signaling have demonstrated that death receptor signaling is required for HDACi-induced apoptosis (observe ref.1and recommendations therein). Conversely, we as well as others have exhibited that whereas HDACi induce expression of death receptors, ligands, and down-regulate inhibitors of death-receptor signaling such as cellular c-FLIP (7) and XIAP (8), the intrinsic rather than the extrinsic pathway is necessary for HDACi-mediated apoptosis (1). We therefore propose that there is a mechanistic rationale for Rabbit polyclonal to Dcp1a combining HDACi with death receptor stimulieither the HDACi will augment death receptor-mediated apoptosis by hyperactivating the same pathway, or the simultaneous activation of the extrinsic and intrinsic apoptotic pathways will result in additive or synergistic killing. Human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, Apo-2L) interacts with two death-inducing receptors, DR4 and DR5, and with three decoy receptors, DcR1, DcR2, and the soluble receptor osteoprotegerin (9). Only one murine, death-inducing receptor has been recognized (mouse DR5) that shares sequence homology with human DR4 and DR5 (10), and two murine decoy receptors have also been recognized (11). In humans, TRAIL can induce tumor cell-selective killing by activating the death-receptor-mediated apoptotic pathway through binding to the TRAIL-R1/DR4 or TRAIL-R2/DR5 receptors, although apoptotic signaling may be regulated by expression of decoy receptors or activation of additional signaling pathways such as the NF-B pathway (9). The therapeutic potential of TRAIL is based on its ability to induce apoptosis in a wide variety of human tumor cell linesin vitroandin vivowith seemingly little toxicity against normal cells (12). Moreover, recombinant soluble Path could be released into nonhuman primates, and early stage clinical studies indicate the fact that agent is certainly nontoxic to human beings (13). Agonistic mAbs that functionally indulge individual and murine Path receptors [HGS-ETR1/mapatumumab (anti-DR4 antibody) and HGS-ETR2/lexatumumab (anti-DR5 antibody) in human beings, and MD5-1 (anti-DR5 antibody) in mice] have already been generated and stimulate Path receptor oligomerization and activate the extrinsic apoptotic cascade, culminating in focus on cell loss of life (1416). These agencies have already been examined in Stage I clinical studies and exhibit exceptional safety information (17,18). The usage of mAb to focus on Path receptors may possess a healing advantage over the usage of recombinant Path because they demonstrate an extended half-lifein vivo, an increased affinity for the mark receptor, no decoy receptor engagement, plus they may provide a system to induce.